NCT03936205View on ClinicalTrials.gov

Dexmedetomidine Addition to Morphine in Patients With Metastatic Cancer

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

October 31, 2017

Study Completion Date

October 31, 2017

Conditions
Refractory PainMetastatic Cancer
Interventions
DRUG

Dexmedetomidine

Patients allocated to this group receive a combination of Morphine and Dexmedetomidine

All Listed Sponsors
lead

Hotel Dieu de France Hospital

OTHER

NCT03936205 - Dexmedetomidine Addition to Morphine in Patients With Metastatic Cancer | Biotech Hunter | Biotech Hunter